Abstract
Background: Emerging HIV drug resistance (HIVDR) poses a growing threat to the long-term success and durability of highly active antiretroviral therapy (HAART).
Objective: To understand the development of HIVDR and estimate the proportion of potential HIVDR and its associated risk factors among the patients on HAART for one year.
Methods: Antiretroviral-naive patients ≥18 years old were invited to participate in this one-year prospective study from seven clinics in Yunnan, Guangxi, and Xinjiang provinces. A questionnaire and blood draw were collected at baseline and 12 month follow-up. The protocol used was modified slightly from the WHO Protocol for Surveys of HIV Drug Resistance Emerging During Treatment and Related Program Factors in Sentinel ART Sites in Resource-limited Settings.
Results: 435 patients were included in the study, of whom 351 (80.7%) were retained at 12 months. The median baseline CD4 cell count of 351 patients retained at 12 months was 132 cells/mm3, which increased to 305 cells/mm3 at 12 months (P < 0.0001), with those from Yunnan and Guangxi receiving d4T/3TC/NVP and Xinjiang receiving AZT/3TC/NVP. Of the total 435 subjects, 417 met the WHO guideline for classification of outcomes based on endpoints, of whom 310 (75.3%) had a viral load < 1000 copies/ml at 12 months (HIVDR prevention), 17 (4.1%) had a viral load ≥ 1000 copies/ml at 12 months and at least one resistance mutation identified, and 90 (21.6%) were classified as potential HIVDR, including 24 with viral loads≥1000 copies/ml at 12 months but no drug resistance mutations, 42 who were lost to followup, and 24 who had discontinued ART by 12 months. In a logistic regression analysis, patients who self-reported missing doses in the previous month were 8.0 fold (95% CI 3.1-20.9) more likely to develop virologic failure than those who did not. and those from Xinjiang were 12.6 fold (95% CI 5.3-29.8) more likely to fail compared to those from Yunnan and Guangxi. Patients with baseline viral load > 100000 were 3.2 fold (95% CI 1.4-6.9) more likely to fail than those whose baseline viral load≤100000. Why Xinjiang was associated with virologic failure was not clear but may be related to the demographics of the participants from Xinjiang, being significantly more IDUs, poorer, and less adherent than those from Yunnan and Guangxi.
Conclusions: Although successful virologic outcomes were seen in the vast majority (75.3%) of those treated at one year, virologic failure continues to be a problem particularly among those less adherent and from Xinjiang. Additional data are needed to understand the generalizability of these results, particularly those related to Xinjiang. For IDUs, enhancing adherence to HAART and considering the treatment of drug addiction as an integral part of the treatment for HIV infection should be considered. As Chinas National Free Antiretroviral Treatment Program continues to mature and improve, ramping up treatment in these settings may be important considerations to the long-term success of the program.
Keywords: Antiretroviral therapy, HIV drug resistance, HIV drug resistance prevention, HIV RNA, China, HAART, NFATP, HIVDR, mutations, Sentinel ART Sites
Current HIV Research
Title: Factors Associated with HIV Virologic Failure Among Patients on HAART for One Year at Three Sentinel Surveillance Sites in China
Volume: 9 Issue: 2
Author(s): Jingyun Li, Yiming Shao, Yuhua Ruan, Ray Y. Chen, Hui Xing, Lingjie Liao, Wei Zheng, Ping Zhong, Laiyi Kang, Xia Wang, Hong Shang, Shaomin Yang, Yonghui Dong, Wei Liu, Shujia Liang, La Zuo, Huiqin Li and Liting Yang
Affiliation:
Keywords: Antiretroviral therapy, HIV drug resistance, HIV drug resistance prevention, HIV RNA, China, HAART, NFATP, HIVDR, mutations, Sentinel ART Sites
Abstract: Background: Emerging HIV drug resistance (HIVDR) poses a growing threat to the long-term success and durability of highly active antiretroviral therapy (HAART).
Objective: To understand the development of HIVDR and estimate the proportion of potential HIVDR and its associated risk factors among the patients on HAART for one year.
Methods: Antiretroviral-naive patients ≥18 years old were invited to participate in this one-year prospective study from seven clinics in Yunnan, Guangxi, and Xinjiang provinces. A questionnaire and blood draw were collected at baseline and 12 month follow-up. The protocol used was modified slightly from the WHO Protocol for Surveys of HIV Drug Resistance Emerging During Treatment and Related Program Factors in Sentinel ART Sites in Resource-limited Settings.
Results: 435 patients were included in the study, of whom 351 (80.7%) were retained at 12 months. The median baseline CD4 cell count of 351 patients retained at 12 months was 132 cells/mm3, which increased to 305 cells/mm3 at 12 months (P < 0.0001), with those from Yunnan and Guangxi receiving d4T/3TC/NVP and Xinjiang receiving AZT/3TC/NVP. Of the total 435 subjects, 417 met the WHO guideline for classification of outcomes based on endpoints, of whom 310 (75.3%) had a viral load < 1000 copies/ml at 12 months (HIVDR prevention), 17 (4.1%) had a viral load ≥ 1000 copies/ml at 12 months and at least one resistance mutation identified, and 90 (21.6%) were classified as potential HIVDR, including 24 with viral loads≥1000 copies/ml at 12 months but no drug resistance mutations, 42 who were lost to followup, and 24 who had discontinued ART by 12 months. In a logistic regression analysis, patients who self-reported missing doses in the previous month were 8.0 fold (95% CI 3.1-20.9) more likely to develop virologic failure than those who did not. and those from Xinjiang were 12.6 fold (95% CI 5.3-29.8) more likely to fail compared to those from Yunnan and Guangxi. Patients with baseline viral load > 100000 were 3.2 fold (95% CI 1.4-6.9) more likely to fail than those whose baseline viral load≤100000. Why Xinjiang was associated with virologic failure was not clear but may be related to the demographics of the participants from Xinjiang, being significantly more IDUs, poorer, and less adherent than those from Yunnan and Guangxi.
Conclusions: Although successful virologic outcomes were seen in the vast majority (75.3%) of those treated at one year, virologic failure continues to be a problem particularly among those less adherent and from Xinjiang. Additional data are needed to understand the generalizability of these results, particularly those related to Xinjiang. For IDUs, enhancing adherence to HAART and considering the treatment of drug addiction as an integral part of the treatment for HIV infection should be considered. As Chinas National Free Antiretroviral Treatment Program continues to mature and improve, ramping up treatment in these settings may be important considerations to the long-term success of the program.
Export Options
About this article
Cite this article as:
Li Jingyun, Shao Yiming, Ruan Yuhua, Y. Chen Ray, Xing Hui, Liao Lingjie, Zheng Wei, Zhong Ping, Kang Laiyi, Wang Xia, Shang Hong, Yang Shaomin, Dong Yonghui, Liu Wei, Liang Shujia, Zuo La, Li Huiqin and Yang Liting, Factors Associated with HIV Virologic Failure Among Patients on HAART for One Year at Three Sentinel Surveillance Sites in China, Current HIV Research 2011; 9 (2) . https://dx.doi.org/10.2174/157016211795569122
DOI https://dx.doi.org/10.2174/157016211795569122 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Integrative Review on Role and Mechanisms of Ghrelin in Stress, Anxiety and Depression
Current Drug Targets Potential Role of Neuroimaging Markers for Early Diagnosis of Dementia in Primary Care
Current Alzheimer Research Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: New Prospects for Treatment of Autoimmune Diseases (Executive Guest Editor: Alessandra Fierabracci)]
Current Pharmaceutical Design New Tacrines as Anti-Alzheimer's Disease Agents. The (Benzo)Chromeno- PyranoTacrines
Current Topics in Medicinal Chemistry Solid-State NMR as a Probe of Amyloid Structure
Protein & Peptide Letters Application of Hot Melt Extrusion Technology in the Development of Abuse-Deterrent Formulations: An Overview
Current Drug Delivery ACE Inhibitor Delapril Prevents Ca<sup>2+</sup>-Dependent Blunting of I<sub>K1</sub> and Ventricular Arrhythmia in Ischemic Heart Disease
Current Molecular Medicine α7 Nicotinic Acetylcholine Receptors: A Therapeutic Target in the Structure Era
Current Drug Targets Consciousness, Functional Networks and Delirium Screening
Current Aging Science Editorial [ Hot Topic: Therapeutic Opportunities in the Treatment of Sleep Disorders (Guest Editor: Margaret Bradbury) ]
CNS & Neurological Disorders - Drug Targets Memories are Made of This (Perhaps): A Review of Serotonin 5-HT6 Receptor Ligands and Their Biological Functions
Current Topics in Medicinal Chemistry The Science of Hypoglycemia in Patients with Diabetes
Current Diabetes Reviews Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Current Neuropharmacology Current Updates in Transdermal Therapeutic Systems and Their Role in Neurological Disorders
Current Protein & Peptide Science Propionate: Hypophagic Effects Observed in Animal Models Might be Transposed to the Human Obesity Management
Current Nutrition & Food Science The Prevalence and Progression of Arterial Calcification in Patients with End-Stage Renal Disease
Vascular Disease Prevention (Discontinued) A Comprehensive Review on Pharmacognostical Investigation and Pharmacology of Typhonium trilobatum
The Natural Products Journal Impact of Aging on the Angiogenic Potential of the Myocardium: Implications for Angiogenic Therapies with Emphasis on Sirtuin Agonists
Recent Patents on Cardiovascular Drug Discovery Role of Ligand-Based Drug Design Methodologies toward the Discovery of New Anti- Alzheimer Agents: Futures Perspectives in Fragment-Based Ligand Design
Current Medicinal Chemistry